Staphylococcal species are a leading cause of community-and nosocomial-acquired infections, where the placement of foreign materials increases infection risk. Indwelling medical devices and prosthetic implants are targets for staphylococcal cell adherence and biofilm formation. Biofilm products actively suppress proinflammatory microbicidal responses, as evident by macrophage polarization toward an anti-inflammatory phenotype and the recruitment of myeloid-derived suppressor cells. With the rise in prosthetic hip and knee arthroplasty procedures, together with the recalcitrance of biofilm infections to antibiotic therapy, it is imperative to better understand the mechanism of crosstalk between biofilm-associated bacteria and host immune cells. This review describes the current understanding of how staphylococcal biofilms evade immune-mediated clearance to establish persistent infections. The findings described herein may facilitate the identification of novel treatments for these devastating biofilm-mediated infections.
Introduction
Skin and nasal colonization with Staphylococcus epidermidis or Staphylococcus aureus is a known risk factor for invasive infections. [1] [2] [3] Prosthetic joint infections (PJIs) likely originate from colonization with small numbers of bacteria, which may provide a window of opportunity for survival if the pathogen does not elicit an initial vigorous immune response to mediate clearance. Staphylococcal invasion at the surgical site followed by adherence to the prosthesis frequently results in biofilm formation [4] [5] [6] ; a community of bacterial cells encased within a self-produced matrix composed of proteins, polysaccharides, and extracellular DNA. 5, 7 The biofilm matrix supports the three-dimensional organization of bacteria while also acting as a barrier against host immune cell invasion. Biofilm development in vitro is a well-characterized process involving an array of proteins required for attachment, maturation, and dispersal 8, 9 ; however, less is understood about staphylococcal biofilm development in vivo. In addition to limited treatment options because of genetically acquired antibiotic resistance, staphylococcal biofilm infections are characterized by inherent antibiotic tolerance due to their dampened metabolic state and decreased susceptibility to phagocytosis. 10 As such, biofilm-mediated PJIs often require surgical revision and replacement of a new prosthesis, which is associated with an increased frequency of infection recurrence and significant morbidity. 11 New approaches to prevent and treat biofilmassociated infections include antiadhesive medical device coatings, therapies which disrupt the biofilm matrix, and antimicrobials targeting biofilm-specific bacterial processes. 12 Until recently, the immune response to staphylococcal biofilm has remained largely unexplored. The scope of this review includes recent advances in our understanding of the effects of staphylococcal biofilm on immune cell function, with particular consideration of macrophage dysfunction and preferential recruitment of myeloidderived suppressor cells (MDSCs). [13] [14] [15] [16] [17] In addition, staphylococcal biofilm products responsible for modifying immune cell function will be discussed. Findings from these studies may unveil a potential two-pronged strategy that limits bacterial biofilm development and coordinates a productive immune response to these infections. Once such strategies become available, the promise is the rate of biofilm-mediated infections will be abated.
Immune Response to Staphylococcal Biofilms
With the rise in acquired antibiotic resistance by staphylococcal species leaving few treatment options, deciphering the innate immune response during device-associated biofilm infections could lead to novel therapeutic strategies. Staphylococcal biofilm infections have Casey M. Gries, PhD Tammy Kielian, PhD
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recently been described to induce an antiinflammatory response, characterized by the recruitment of alternatively activated macrophages and MDSC expansion. These two events, described in detail below, polarize the local environment toward an anti-inflammatory and profibrotic milieu, thereby contributing to the chronic nature of biofilm infections. The findings described below raise the possibility for future approaches aimed at targeting immune cell activity to mount a productive microbicidal response to clear PJIs.
Alternatively Activated Macrophages
Considered among the first lines of innate immune cellular defense against bacterial infections, resident tissue macrophages can be classically activated (proinflammatory) or alternatively activated (anti-inflammatory) depending on the inflammatory milieu. We will not utilize the M1/M2 nomenclature in this review to describe macrophage activation states because the original intent of the M1/M2 dichotomy was to describe macrophage responses to well-controlled in vitro conditions, 18 which is clearly not the case in vivo. This is reflected by many reports demonstrating that macrophages can simultaneously possess gene-expression profiles indicative of both M1 and M2 states. 19, 20 Instead, we will refer to general functional attributes of macrophages in response to biofilm-associated bacteria, keeping in mind that responses are likely more complicated. Classically activated macrophages are essential effectors during planktonic bacterial infection, in part, through their robust proinflammatory cytokine production, phagocytosis, and killing by generation of reactive oxygen and nitrogen species. The proinflammatory macrophage response is characterized by inducible nitric oxide synthase (iNOS), tumor necrosis factor-alpha (TNF-a), interleukin-1 beta (IL-1ß), and interferon gamma (IFN-ɣ) expression, which promote bacterial clearance, whereas antiinflammatory mediators, such as arginase-1 (Arg-1), IL-4, and IL-10, attenuate macrophage microbicidal activity and promote a profibrotic environment, facilitating bacterial persistence. Recent studies by our laboratory and others have shown that staphylococcal biofilms evade toll-like receptors 2 (TLR2) and 9 (TLR9) recognition and skew host leukocytes toward an anti-inflammatory, profibrotic response, evidenced by increased Arg-1 and decreased iNOS expression. [21] [22] [23] [24] This alternatively activated response induces robust fibrosis surrounding the biofilm, effectively preventing macrophage invasion and phagocytosis of biofilm-associated bacteria, favoring biofilm persistence. 15, 25, 26 Although proinflammatory cytokine production is detected during S aureus biofilm infections, this response is clearly not sufficient to mitigate biofilm growth or survival. [13] [14] [15] 27 This suggests a primary defect in the phagocytes that normally clear bacteria, which is supported by the preferential recruitment of MDSCs into staphylococcal biofilms that possess anti-inflammatory properties by preventing macrophage proinflammatory activity and T cell activation.
To circumnavigate the anti-inflammatory milieu induced by S aureus biofilms, an activated macrophage-adoptive transfer strategy was employed by Hanke et al 25 in a catheterassociated model of S aureus biofilm infection. Because earlier work revealed the inability of resident tissue macrophages to invade the biofilm properly, this approach addressed whether the direct injection of proinflammatory activated macrophages (IFN-ɣ 1 peptidoglycan) into biofilms would transform the inflammatory milieu to facilitate biofilm clearance. Injection of activated macrophages during early biofilm formation augmented proinflammatory cytokine production, reduced macrophage Arg-1 expression, and limited S aureus biofilm development. Proinflammatory macrophage polarization was also shown to increase phagocytosis and killing of S aureus biofilms in vitro. Furthermore, treatment of mice with the C5a receptor (CD88) agonist EP67, which invokes macrophage proinflammatory activity, augmented macrophage infiltration and proinflammatory mediator expression in biofilm-infected tissues, which translated into reduced S aureus biofilm growth. 25 Taken together, these findings demonstrate that S aureus biofilms interfere with antibacterial effector mechanisms of resident tissue macrophages, which is an essential step for biofilm development. However, if proinflammatory macrophages gain access to sites of S aureus biofilm (ie, by direct inoculation), they are capable of exerting antibacterial activity that manifests as improved biofilm clearance. This supports an important role for S aureus in thwarting early macrophage activation to establish chronic S aureus biofilm infections.
Myeloid-derived Suppressor Cells
Suppression of proinflammatory responses by MDSCs have been demonstrated in a number of cancer and bacterial infection models. [28] [29] [30] [31] MDSCs are a heterogeneous population of immature monocytes and granulocytes, and are functionally characterized by their ability to suppress T cell activation in an antigendependent or antigen-independent manner (reviewed in Ref. 32) . Depending on the local tissue microenvironment, infiltrating MDSCs can either maintain their suppressive properties or differentiate into mature neutrophils, macrophages, or dendritic cells. Our laboratory was the first to report MDSC recruitment (CD11b 1 Ly-6G 1 Ly-6C high ) in a mouse model of S aureus PJI, which was confirmed by the identification of MDSC-like cell populations in human PJIs, including those caused by S epidermidis. 13, 15 Subsequently, other groups have reported MDSC recruitment together with immunosuppressive activity in mouse models of S aureus cutaneous infection 33 and to the kidneys following S aureus sepsis. 17 In assessing the functional role of MDSCs in establishing the suppressive environment surrounding S aureus biofilms, an antibodymediated depletion strategy was used to target Ly-6G 1 cells. Any responses would be attributed to MDSC activity; although Ly6G is also expressed on neutrophils, our previous work has shown that few neutrophils are recruited to S aureus biofilms. Importantly, Ly6G treatment would leave CD11b 1 Ly-6C high Ly-6G 2 monocytes intact, which was predicted to enhance monocyte/macrophage proinflammatory and bactericidal activity in the context of reduced MDSC inhibitory signals. This was indeed the case, where Ly6G-depleted animals displayed significantly increased proinflammatory mediator production (ie, IL-1ß and G-CSF) that translated into reduced S aureus burdens in a mouse PJI model. 13 To directly demonstrate enhanced monocyte/macrophage microbicidal activity in the context of MDSC depletion, mice were treated with Gr-1 antibody, which targets both Ly-6G 1 Ly-6C high MDSCs and Ly-6G 2 Ly-6C high monocytes. This approach resulted in significantly higher S aureus biofilm burdens, which was attributed to the fact that although MDSC inhibition was removed, effector phagocytes (ie, monocytes/macrophages) were reduced, leading to unchecked biofilm expansion. 13 These data demonstrate that MDSCs actively suppress monocyte/macrophage proinflammatory activity, which is important for biofilm persistence. Interestingly, Gr-1 1 depletion in a S aureus sepsis model had no effect on bacterial burdens 17 ; however, this is not a biofilm infection, and mature macrophages are not present in the bloodstream, and as such, the modes of bacterial clearance differ.
A role for both IL-12 and IL-10 signaling has been reported to shape the anti-inflammatory biofilm milieu by promoting MDSC recruitment; however, the kinetics of cytokine involvement differ. 14,15 Namely, IL-12 deficiency leads to an early reduction in MDSCs, whereas IL-10 affects later MDSC recruitment into S aureus biofilms ( Figure 1) . As a result of reduced MDSC infiltrates, monocyte influx was increased in both IL-12 and IL-10 knockout (KO) mice, and these monocytes displayed increased proinflammatory activity that translated into decreased S aureus biofilm burdens.
Importantly, adoptive transfer of wild-type MDSCs into IL-12 and IL-10 KO animals returned biofilm growth to levels seen in wild-type animals. 14, 15 Adoptive transfer of MDSCs also exacerbated infection outcome in a mouse model of S aureus sepsis, again supporting the functional role of MDSCs in promoting bacterial expansion. 33 
T Cells
The role of T cells in mediating staphylococcal biofilm PJIs remains unclear. Our laboratory has found minimal T cell infiltrates in a mouse S aureus PJI model, 14, 15 and T cells were undetectable in human PJIs compared with tissues recovered from aseptic orthopedic revisions, where a prominent T cell population was observed. 15 The relative paucity of T cells in both human PJIs and our mouse PJI model could be explained by the robust MDSC infiltrate associated with these infections based on their ability to inhibit T cell proliferation/activation. 13 In contrast to our studies, other works have reported a role for Th1 and Th17 cells in response to S aureus biofilms. 34 These discrepancies may be explained by the distinct model systems employed; namely, the use of a tibial implant precoated in vitro with an established biofilm compared with that in our approach where a sterile orthopedic implant is infected in vivo using a 200-fold lower bacterial dose. Indeed, we recently reported that increasing the infectious inoculum from 10 3 to 10 5 CFU in the mouse PJI model altered leukocyte recruitment and inflammatory mediator production as well as biofilm growth/clearance. 27 This highlights the need to carefully consider infectious doses when examining inflammatory attributes of biofilm infection, in particular, to their relevance in terms of modeling events that might occur during native PJI in humans.
Part 1: Conclusions
In contrast to planktonic bacteria, the immune response to staphylococcal biofilms is suppressive and polarizes macrophages toward an anti-inflammatory state. This is, in part, because of MDSC recruitment that attenuates monocyte/ macrophage activation. Importantly, similar leukocyte infiltration patterns are observed between the mouse PJI model and human PJI tissues, including increased MDSC-like cells and few T cells. Limiting MDSC influx and/or their immunosuppressive action may offer a new therapeutic strategy to thwart chronic staphylococcal biofilm infections.
While biofilm invasion and phagocytosis by neutrophils seem to be less affected than macrophages, 21, 35, 36 studies have suggested that neutrophils recovered from human implant/ endoprosthesis infections are less phagocytic and contribute to infection persistence. 37 This may result from the inhibition of opsonophagocytic killing of S epidermidis biofilms compared with planktonic cells. 38 In the S epidermidis biofilm matrix, polysaccharide intracellular adhesion has been shown to play an important role in preventing macrophage 23 and neutrophil phagocytosis. 39 Another model of S epidermidis biofilm formation on peritoneal dialysis catheters reported defective macrophage function that was linked to reduced IFN-ɣ production. 40 With regard to S aureus, it is interesting that the biofilm transcriptome remained relatively unaffected in the face of neutrophil challenge, whereas a large percentage of genes (95%) were significantly downregulated on macrophage exposure. 36 These experiments demonstrate that S aureus biofilms differentially modify their gene expression patterns depending on the leukocyte subset encountered. The finding that biofilms were more responsive following macrophage addition rather than neutrophils is in agreement with the preferential recruitment of macrophages but minimal neutrophils during biofilm formation. [13] [14] [15] [16] 21, [25] [26] [27] While the anti-inflammatory response seems to be driven, in part, by biofilm products, the specific effectors and their mechanism of action are yet to be fully elucidated.
Biofilm Effectors of Immune Cell Dysfunction
In general, PJIs associated with more virulent organisms, such as S aureus, often present within the first 3 months after surgery, whereas complications triggered by less virulent organisms, such as S epidermidis, can manifest as chronic infections months or years after surgery. 11, 41 This dichotomy may reflect a passive defense strategy in S epidermidis rather than the broad arsenal of toxins and other virulence determinants that S aureus possesses. 42 Interestingly, as mentioned earlier, coculture of macrophages with S aureus biofilm resulted in a global suppression of S aureus transcription, whereas only a few genes were upregulated. 36 This suggests that S aureus may "hide" from the immune system by globally repressing gene expression 43 ; however, it is clear that proteins and other molecules released from S aureus biofilm also affect macrophage function. 16 Identification of candidate molecules responsible for inhibiting macrophage proinflammatory properties represents an essential step in understanding host-pathogen interactions during PJI. The second part of this review Figure 1 Model for S aureus biofilm immune evasion. Toxins secreted from S aureus biofilms, including a-toxin (Hla) and Staphylococcus aureus leukocidin A/B (LukAB), inhibit macrophage microbicidal function and induce cell death. Additional unidentified molecules released from staphylococcal biofilms, either via active secretion or following bacterial cell lysis, likely contribute to maximize inhibition of host antimicrobial activity. MDSC recruitment by a yet unknown mechanism or mechanisms that require IL-12 suppresses T cell activity and induces a local antiinflammatory milieu characterized by IL-10 production. Biofilm-mediated immune polarization results in biofilm persistence and chronic disease. MDSC = myeloid-derived suppressor cell.
focuses on secreted factors that induce immune cell dysfunction, with a particular focus on macrophages.
Toxins S aureus produces a wide array of cell wallassociated and secreted virulence factors that interfere with antimicrobial effectors of the immune system. 44, 45 Two well-studied toxins include a-toxin (Hla), which acts on red blood cells and leukocytes by binding to ADAM10, 46, 47 and the bicomponent leukocidins Staphylococcus aureus leukocidin A/B (LukAB), 48 Staphylococcus aureus leukotoxin ED (LukED), 49 and Panton-Valentine leukocidin (PVL, consisting of LukFS), 50 which bind to specific leukocyte surface receptors. S aureus also produces enterotoxins, such as toxic shock syndrome toxin; however, they will not be discussed in this review. As mentioned above, S epidermidis does not produce many toxins 51 but rather relies on a thick biofilm matrix and extensive polysaccharide network for immune evasion. For this reason, the remainder of this section will focus on S aureus biofilm components and their effects on antimicrobial immune mechanisms.
While biofilm size and matrix density represent physical obstacles for macrophage invasion, our laboratory recently demonstrated that macrophage phagocytosis was significantly attenuated following exposure to the S aureus biofilm-conditioned medium. 16 Restoration of phagocytosis was achieved following the treatment of biofilm supernatant with proteinase K, indicating that a secreted proteinaceous factor or factors actively inhibit macrophage phagocytosis of S aureus biofilm. Mutation in the accessory gene regulator (agr) locus also alleviated the macrophage phagocytic block, suggesting that the putative proteins were regulated in an agr-dependent manner. 16 Subsequent experiments demonstrated that LukAB and a-toxin act in a synergistic manner to prevent macrophage phagocytosis and are also important for inhibiting macrophage invasion in vivo in a mouse PJI model, which translates into biofilm persistence. 16 However, it is clear that additional extracellular factors released from S aureus biofilms play a role in thwarting macrophage activation because the phagocytic block was not completely reversed following simultaneous inhibition of a-toxin/LukAB activity. 16 This is not unexpected, given the extensive arsenal of virulence determinants expressed by S aureus, which may represent viable therapeutic targets to augment macrophage microbicidal activity.
Intracellular Components
Cell death and lysis is an essential mechanism in staphylococcal biofilm development, as demonstrated by mutation in genes responsible for autolysis 52, 53 or treatment with an inhibitor of autolysis, polyanethol sulfonate (PAS). 54, 55 Intracellular molecules, such as DNA, are important components of the biofilm matrix, 5 and while this represents a potential pathogenassociated molecular pattern (PAMP) to trigger proinflammatory activity through TLR9, we have previously shown that S aureus biofilms evade TLR9-mediated recognition of bacterial DNA. 21 The potential of secreted molecules from S aureus biofilm to induce macrophage dysfunction was recently addressed by Scherr et al. 16 Namely, treatment of macrophages with conditioned medium from mature S aureus biofilms prevented macrophage phagocytosis. 21 S aureus biofilms treated with lysostaphin were no longer able to inhibit macrophage phagocytosis, suggesting that the bioactive molecule or molecules were not released following cell lysis. This was confirmed by the fact that a conditioned medium from PAS-treated biofilms was still capable of blocking macrophage phagocytosis and was proteinase K sensitive, indicating that secreted proteins are responsible for the observed macrophage dysfunction. 16 However, unpublished observations from our laboratory also suggest that small molecules released through autolysis can escape from the biofilm matrix and affect immune cell activity because conditioned medium from PAStreated biofilms can also alter macrophage gene-expression profiles. Together, these findings suggest that large bacterial pathogenassociated molecular patterns capable of eliciting robust proinflammatory activity (ie, eDNA released during autolysis) are buried within the biofilm matrix and are inaccessible to macrophages based on their inability to invade the biofilm, whereas smaller molecules diffuse from the biofilm and, as such, are capable of interacting with proximal immune cells to trigger a nonproductive immune response typified by phagocytic impairments and cell death. Therefore, therapeutics targeting biofilm matrix disruption hold interesting potential for augmenting leukocyte microbicidal activity and biofilm clearance.
Part 2: Conclusions
S aureus biofilms interfere with microbicidal immune responses, in part, by polarizing macrophages toward an anti-inflammatory, profibrotic phenotype. While gene-expression profiles in S aureus biofilms are transiently but globally repressed following macrophage exposure, 36 secreted proteins enriched during S aureus biofilm growth, including a-toxin and LukAB, are capable of inducing macrophage dysfunction. 16 Other potential proteins or molecules responsible for inhibiting macrophage anti-biofilm activity remain to be identified. Additionally, further investigation into the role of biofilm molecules that are actively secreted or released following bacterial lysis that promotes MDSC recruitment/ activity will shed light on critical biofilm processes that contribute to the establishment of chronic PJIs.
Final Remarks
The work discussed in this review details recent advances in the molecular crosstalk between staphylococcal biofilms and host immune cells (Figure 1) . Microbial-immune cell interactions have proven to be important factors during biofilm infections, and these studies help advance the knowledge of how bacteria manipulate host immune responses. Staphylococcal biofilms have evolved effective mechanisms to establish chronic infections, in part, by actively preventing macrophage phagocytosis and proinflammatory activity. Evidence suggests that this is due to the action of MDSCs recruited to the site of staphylococcal PJI, which inhibit monocyte/macrophage proinflammatory action and biofilm clearance. The role of MDSCs on mediating T cell suppression during biofilm formation remains unclear; however, they may play a significant role in the failure to induce protective adaptive immunity during staphylococcal PJIs. Preventing the suppressive activity of infiltrating MDSCs may prove to be a novel therapeutic strategy to thwart PJIs; however, it remains unclear whether biofilm products directly contribute to MDSC accumulation by arresting their maturation or if staphylococcal biofilms cooperate with MDSCs to inhibit immune effector function. These questions represent areas of active investigation in our laboratory.
